Perspective Therapeutics Q1 2024 GAAP EPS $(0.02) Beats $(0.03) Estimate, Sales $325.000K Up From $233.000K YoY
Portfolio Pulse from Benzinga Newsdesk
Perspective Therapeutics reported a Q1 2024 GAAP EPS of $(0.02), beating the estimate of $(0.03). Sales increased to $325,000 from $233,000 year-over-year.
May 15, 2024 | 11:04 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Perspective Therapeutics (CATX) reported better-than-expected Q1 2024 GAAP EPS of $(0.02) compared to the $(0.03) estimate. Sales also saw a significant year-over-year increase to $325,000 from $233,000.
The better-than-expected EPS and significant year-over-year sales growth are positive indicators for Perspective Therapeutics (CATX). This performance is likely to boost investor confidence and positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100